Peptonic Medical AB Granted Patent in Australia: Vernivia Secures Exclusivity Until 2038
Peptonic Medical AB (publ) ("Peptonic") has received notification that the Australian patent office has granted the FOAM II patent. This patent provides broad protection for Peptonic's self-care product Vernivia, an over-the-counter and antibiotic-free treatment for bacterial vaginosis, as well as the company's mousse-based drug delivery technology Venerol. The patent extends until May 2038, ensuring Vernivia's market exclusivity.Bacterial vaginosis is very common, especially among women of reproductive age, affecting approximately one in three women. Vernivia is the first clinically proven
